Littérature scientifique sur le sujet « PDE4 inhibitor »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « PDE4 inhibitor ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "PDE4 inhibitor"
ERDOGAN, Suat, et Miles D. HOUSLAY. « Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant ». Biochemical Journal 321, no 1 (1 janvier 1997) : 165–75. http://dx.doi.org/10.1042/bj3210165.
Texte intégralWang, Huanchen, Ming-Sheng Peng, Yi Chen, Jie Geng, Howard Robinson, Miles D. Houslay, Jiwen Cai et Hengming Ke. « Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors ». Biochemical Journal 408, no 2 (14 novembre 2007) : 193–201. http://dx.doi.org/10.1042/bj20070970.
Texte intégralBoyd, Abigail, Ileana V. Aragon, Lina Abou Saleh, Dylan Southers et Wito Richter. « The cAMP-phosphodiesterase 4 (PDE4) controls β-adrenoceptor- and CFTR-dependent saliva secretion in mice ». Biochemical Journal 478, no 10 (24 mai 2021) : 1891–906. http://dx.doi.org/10.1042/bcj20210212.
Texte intégralXu, Man, Xiaowen Yu, Xia Meng, Songming Huang, Yue Zhang, Aihua Zhang et Zhanjun Jia. « Inhibition of PDE4/PDE4B improves renal function and ameliorates inflammation in cisplatin-induced acute kidney injury ». American Journal of Physiology-Renal Physiology 318, no 3 (1 mars 2020) : F576—F588. http://dx.doi.org/10.1152/ajprenal.00477.2019.
Texte intégralAbusnina, Abdurazzag, Thérèse Keravis, Qingwei Zhou, Hélène Justiniano, Annelise Lobstein et Claire Lugnier. « Tumour growth inhibition and anti-angiogenic effects using curcumin correspond to combined PDE2 and PDE4 inhibition ». Thrombosis and Haemostasis 113, no 02 (mars 2015) : 319–28. http://dx.doi.org/10.1160/th14-05-0454.
Texte intégralFavot, Laure, Thérèse Keravis, Vincent Holl, Alain Bec et Claire Lugnier. « VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors ». Thrombosis and Haemostasis 90, no 08 (2003) : 334–43. http://dx.doi.org/10.1160/th03-02-0084.
Texte intégralIvey, F. Douglas, Lili Wang, Didem Demirbas, Christina Allain et Charles S. Hoffman. « Development of a Fission Yeast-Based High-Throughput Screen to Identify Chemical Regulators of cAMP Phosphodiesterases ». Journal of Biomolecular Screening 13, no 1 (26 novembre 2007) : 62–71. http://dx.doi.org/10.1177/1087057107312127.
Texte intégralYougbare, Issaka, Caroline Morin, Farid Yannick Senouvo, Chantal Sirois, Roula Albadine, Claire Lugnier et Eric Rousseau. « NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues ». American Journal of Physiology-Lung Cellular and Molecular Physiology 301, no 4 (octobre 2011) : L441—L450. http://dx.doi.org/10.1152/ajplung.00407.2010.
Texte intégralBoyd, Abigail, Ileana Aragon, Justin Rich, Will McDonough, Marianna Oditt, Daniel Irelan, Edward Fiedler, Lina Abou Saleh et Wito Richter. « Assessment of PDE4 Inhibitor-Induced Hypothermia as a Correlate of Nausea in Mice ». Biology 10, no 12 (20 décembre 2021) : 1355. http://dx.doi.org/10.3390/biology10121355.
Texte intégralMurthy, Karnam S., Huiping Zhou et Gabriel M. Makhlouf. « PKA-dependent activation of PDE3A and PDE4 and inhibition of adenylyl cyclase V/VI in smooth muscle ». American Journal of Physiology-Cell Physiology 282, no 3 (1 mars 2002) : C508—C517. http://dx.doi.org/10.1152/ajpcell.00373.2001.
Texte intégralThèses sur le sujet "PDE4 inhibitor"
Reid, Anne Marie. « Raf-1 kinase inhibitor protein modulation of the cellular response to chemotherapeutic drugs and PDE5 inhibitors ». Thesis, University of Glasgow, 2011. http://theses.gla.ac.uk/2497/.
Texte intégralKurian, Stefanie [Verfasser]. « Effects of combination therapy of PDE5 inhibitor sildenafil and multikinase inhibitors sorafenib and sunitinib in NSCLC / Stefanie Kurian ». Gießen : Universitätsbibliothek, 2015. http://d-nb.info/1076760546/34.
Texte intégralWang, Guocheng. « Design, synthesis and development of PDE5 inhibitors ». Thesis, Aston University, 2009. http://publications.aston.ac.uk/15405/.
Texte intégralStrange, Julian William Nevill. « PDE5 inhibition in pulmonary arterial hypertension ». Thesis, Imperial College London, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.441986.
Texte intégralNGUYEN, HOANG OANH. « ANTI-INFLAMMATORY PROPERTIES OF PDE4 INHIBITION IN SARS-COV-2-ACTIVATED HUMAN DENDRITIC CELLS ». Doctoral thesis, Università degli studi di Brescia, 2022. http://hdl.handle.net/11379/555422.
Texte intégralDysfunctional immune response and hyper-inflammation with subsequent cytokine storm were shown to play a key role in the development of severe and fatal forms of Coronavirus disease 2019 (COVID-19). This clinical condition suggests that an overactive innate immune response may unleash virus-dependent immune pathology. Here, we described a novel mechanism of SARS-CoV-2-dependent activation of dendritic cells (DCs), based on the recognition of sequences of viral genomic ssRNA (SCV2-RNA) by endosomal pattern recognition receptors, namely TLR7 and TLR8. Importantly, SCV2-RNA recapitulated potent lung inflammation in vivo as shown by accumulation of proinflammatory mediators and immune cell infiltration; and induced a strong release of pro-inflammatory cytokines and Th1 polarization in vitro. Tanimilast is a novel and selective inhaled inhibitor of phosphodiesterases 4 that is in advanced clinical development for the treatment of chronic obstructive pulmonary disease and could prove beneficial in severe COVID-19 pneumonia. In our experimental setting, the potent activation of DCs by SCV2-RNA was severely blunted by Tanimilast, which decreased the release of pro-inflammatory cytokines (TNF-α and IL-6), chemokines (CCL3, CXCL9, and CXCL10) and of Th1-polarizing cytokines (IL-12, type I IFNs). However, Tanimilast did not impair the acquisition of the maturation markers CD83, CD86, HLA-DR and CCR7. Consistent with this, Tanimilast did not reduce the capability of activated DCs to activate CD4+ T cells but skewed their polarization towards a Th2 phenotype. In addition, Tanimilast blocked the increase of HLA class I molecules and restrained the proliferation and activation of cytotoxic CD8+ T cells accordingly. The immune-modulatory effects of Tanimilast were further demonstrated by its capacity to enhance cAMP-dependent immunosuppressive molecules such as IDO1, TSP1, VEGFA and Amphiregulin in LPS-stimulated DCs. These cells also strongly upregulated CD141 and displayed increased uptake of dead cells. Altogether, our results indicate that Tanimilast induce mature DCs to acquire immunomodulatory properties as well as a distinct semi-mature phenotype, associated with the prominent expression of CD141, thus proposing Tanimilast as a promising immunomodulatory drug for the treatment in inflammatory or immune-mediated diseases, possibly including severe COVID-19 pneumonia.
LI, HONGWU. « Phosphodiesterase 7(PDE7) inhibitors : a new target to treat drug addiction ». Doctoral thesis, Università degli Studi di Camerino, 2015. http://hdl.handle.net/11581/401772.
Texte intégralTippelt, Sabine [Verfasser]. « Untersuchung der Pathogenese der möglicherweise speziesspezifischen toxikologischen Effekte von PDE4-Inhibitoren bei Ratten / Sabine Tippelt ». Hannover : Bibliothek der Tierärztlichen Hochschule Hannover, 2013. http://d-nb.info/1037885198/34.
Texte intégralXu, Chenjia. « A Novel in vitro PDE7 Inhibitor Inhibits IL-2 Gene Expression in Activated T Cells and Induces Apoptosis in a B-cell Line and Monocytic Cell Line ». Thesis, Boston College, 2013. http://hdl.handle.net/2345/3935.
Texte intégralElevating intracellular cAMP levels can result in a wide range of anti-inflammatory effects and growth arrest and apoptosis in cancer cells, marking phosphodiesterases (PDEs) as potential targets for inflammatory diseases and cancer treatment. PDE7A is proposed to be a new therapeutic target for its ubiquitous expression in proinflammatory and immune cells. A Barbituric acid based compound, BC12 was identified as an in vitro PDE7 inhibitor in fission-yeast-based high-throughput screen. Analysis of this compound on the activation of Jurkat T lymphocytes, mouse and human primary T cells reveals inhibition of IL-2 production, though cell viability is not significantly impacted. Real-time RT-PCR and mRNA stability assays indicate that the inhibition of IL-2 production by BC12 is attributable to transcriptional repression without accelerating IL-2 mRNA decay. By contrast, compounds of similar structure with that of BC12 exhibit varying effects on IL-2 production that does not correlate with their in vitro PDE7 inhibitory activity, suggesting that the in vivo target of BC12 responsible for these effects may not be PDE7. Our study further reveals that BC12 inhibits IL-2 transcription through targeting NFAT and NFkB-mediated pathways. Preliminary investigation on other T helper cell cytokine secretion indicates that BC12 has a potential to selectively inhibit Th2 cytokines. Our data suggest that BC12 may present a novel anti-inflammatory drug for its immunosuppressive and potential immunomodulatory effects. Analysis of BC12 on a human B-cell line and a monocytic cell line demonstrate its pro-apoptotic effects in a dose-dependent manner. Titration of BC12 on human diffuse large B-cell lymphoma (DLBCL), LY18 cells, and human primary B cells reveals that BC12 induces cell death more effectively in DLBCL LY18 cells than normal B cells, suggesting the anti-cancer potential of this compound
Thesis (PhD) — Boston College, 2013
Submitted to: Boston College. Graduate School of Arts and Sciences
Discipline: Biology
Grommel, Sonja [Verfasser]. « Untersuchung möglicher positiver Effekte hinsichtlich der Aufrechterhaltung der Gravidität durch PDE4-Inhibitoren an Ratten / Sonja Grommel ». Hannover : Bibliothek der Tierärztlichen Hochschule Hannover, 2013. http://d-nb.info/1037800826/34.
Texte intégralClapham, John Christopher. « Characterisation and structural studies on dog heart cyclic nucleotide phosphodiesterase ». Thesis, Birkbeck (University of London), 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.267913.
Texte intégralLivres sur le sujet "PDE4 inhibitor"
Behrens, Frank, Michaela Koehm et Michael J. Parnham. Synthetic DMARDs. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198737582.003.0028.
Texte intégralPorst, Hartmut. Erectile dysfunction. Sous la direction de David John Ralph. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0103.
Texte intégralChapitres de livres sur le sujet "PDE4 inhibitor"
McAllister-Williams, R. Hamish, Daniel Bertrand, Hans Rollema, Raymond S. Hurst, Linda P. Spear, Tim C. Kirkham, Thomas Steckler et al. « PDE4 Inhibitors ». Dans Encyclopedia of Psychopharmacology, 977. Berlin, Heidelberg : Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_1541.
Texte intégralMcAllister-Williams, R. Hamish, Daniel Bertrand, Hans Rollema, Raymond S. Hurst, Linda P. Spear, Tim C. Kirkham, Thomas Steckler et al. « PDE3 Inhibitors ». Dans Encyclopedia of Psychopharmacology, 976–77. Berlin, Heidelberg : Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_1540.
Texte intégralMcAllister-Williams, R. Hamish, Daniel Bertrand, Hans Rollema, Raymond S. Hurst, Linda P. Spear, Tim C. Kirkham, Thomas Steckler et al. « PDE5 Inhibitors ». Dans Encyclopedia of Psychopharmacology, 977. Berlin, Heidelberg : Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_1542.
Texte intégralMcAllister-Williams, R. Hamish, Daniel Bertrand, Hans Rollema, Raymond S. Hurst, Linda P. Spear, Tim C. Kirkham, Thomas Steckler et al. « PDE Inhibitors ». Dans Encyclopedia of Psychopharmacology, 976. Berlin, Heidelberg : Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_3466.
Texte intégralPetroianu, Georg, et Peter Michael Osswald. « Phosphodiesterase(PDE)-Inhibitoren ». Dans Anästhesie in Frage und Antwort, 155–57. Berlin, Heidelberg : Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-662-05715-5_54.
Texte intégralGresele, Paolo, Stefania Momi et Emanuela Falcinelli. « Dipyridamole and PDE Inhibitors ». Dans Platelets in Thrombotic and Non-Thrombotic Disorders, 1283–98. Cham : Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-47462-5_86.
Texte intégralDrobnis, Erma Z., et Ajay K. Nangia. « Phosphodiesterase Inhibitors (PDE Inhibitors) and Male Reproduction ». Dans Impacts of Medications on Male Fertility, 29–38. Cham : Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-69535-8_5.
Texte intégralPadma-Nathan, Harin. « Sildenafil Citrate, the Classic PDE5 Inhibitor ». Dans Oral Pharmacotherapy for Male Sexual Dysfunction, 65–83. Totowa, NJ : Humana Press, 2005. http://dx.doi.org/10.1385/1-59259-871-4:065.
Texte intégralJackson, Graham. « The Hemodynamics of Phosphodiesterase-PDE5 Inhibitors ». Dans Heart Disease and Erectile Dysfunction, 131–37. Totowa, NJ : Humana Press, 2004. http://dx.doi.org/10.1007/978-1-59259-748-2_8.
Texte intégralFrancis, Sharron H., et Jackie D. Corbin. « Sildenafil, pharmacology of a highly selective PDE5 inhibitor ». Dans Sildenafil, 15–33. Basel : Birkhäuser Basel, 2004. http://dx.doi.org/10.1007/978-3-0348-7945-3_2.
Texte intégralActes de conférences sur le sujet "PDE4 inhibitor"
Chen, W., Z. Xu, H. Wee, G. S. Lewis, N. Olsen, J. Lin et S. G. Zheng. « THU0097 Phosphodiesterases 4 (PDE4) inhibitor ameliorates experimental arthritis ». Dans Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.4989.
Texte intégralTakeda, K., Y. Shiraishi, J. Domenico, JE Loader, S. Sanjar, JJ Lucas et EW Gelfand. « Combined Effects of the Phosphodiesterase Type 4 (PDE4) Inhibitor, Roflumilast, and the PDE5 Inhibitor, Tadalafil, in Allergen-Induced Airway Hyperresponsiveness (AHR). » Dans American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a5717.
Texte intégralBeretz, A., F. Lanza, A. Stierlé et J.-P. Cazenave. « CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS PREVENT AGGREGATION AND SECRETION OF HUMAN PLATELETS BY RAISING CYCLIC AMP AND REDUCING CYTOPLASMIC FREE CALCIUM MOBILIZATION ». Dans XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643586.
Texte intégralBridgewood, C., R. Cuthbert, M. Wittmann et D. McGonagle. « AB0054 Pde4 inhibitor attenuation of il-23 secretion from mononuclear cells ». Dans Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.7287.
Texte intégralRheault, Tara, Thomas Bengtsson et Kathleen Rickard. « Ensifentrine, a dual PDE3/PDE4 inhibitor, improves FEV1 regardless of smoking status or history of chronic bronchitis ». Dans ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.4786.
Texte intégralChapman, Richard W., Aileen House, Jennifer Richard, Xiomara Fernandez, Howard Jones, Dan Prelusky, James Lamca et al. « Pharmacology Of SCH900182, A Potent, Selective Inhibitor Of PDE4 For Inhaled Administration ». Dans American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a5671.
Texte intégralKistemaker, Loes E. M., Tjitske A. Oenema, Wim A. de Jager, I. Sophie T. Bos, Fabrizio Facchinetti, Gino Villetti et Reinoud Gosens. « LATE-BREAKING ABSTRACT : The PDE4 inhibitor CHF-6001 and LAMAs cooperatively inhibit bronchoconstriction-induced remodeling in lung slices ». Dans ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.oa1974.
Texte intégralLucci, Germano, Fabrizia Mariotti, Debora Santoro, Daniela Acerbi, Gianluigi Poli et Marie-Anna Nandeuil. « Safety, tolerability and pharmacokinetics of CHF 6001, a novel selective inhaled PDE4 inhibitor, in healthy volunteers ». Dans ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa4086.
Texte intégralKnowles, RG, DI Ball, MH Gascoigne, C. Tralau-Stewart et AT Nials. « In VivoCharacterisation of GSK256066, an Exceptionally High Affinity and Selective PDE4 Inhibitor Suitable for Topical Administration. » Dans American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4582.
Texte intégralKubera, JE, FJ Schlerman, KH Nocka, RM Greco, CM Williams et JP Sypek. « Characterization of Anti-Inflammatory Effects of a PDE4 Inhibitor in a Model of Acute Smoke Exposure. » Dans American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a5641.
Texte intégralRapports d'organisations sur le sujet "PDE4 inhibitor"
Are all PDE5 inhibitors the same ? BJUI Knowledge, mars 2018. http://dx.doi.org/10.18591/bjuik.0470.
Texte intégralMedical management of priapism, with a focus on PDE5 inhibitors. BJUI Knowledge, janvier 2016. http://dx.doi.org/10.18591/bjuik.0610.
Texte intégral